Krystal Biotech (KRYS) Treasury Shares (2021 - 2026)
Krystal Biotech (KRYS) posted quarterly Treasury Shares of $304491.0 for Q2 2026, down 10.15% year-over-year from $338878.0 in Q2 2025, and down 1.84% on a QoQ basis from $310184.0 in Q1 2026.
Krystal Biotech (KRYS) Treasury Shares (2021 - 2026) Analysis & Trends
Krystal Biotech has reported Treasury Shares for 6 years, with the latest figure at $304491.0 in Q2 2026.
- Treasury Shares for Q2 2026 came in at $304491.0, down 10.15% year-over-year; the trailing twelve-month figure through Jun 2026 was $304491.0 (down 10.15% YoY), and the FY2025 annual result was $331574.0, up 7.62% from the prior year.
- Treasury Shares retreated to $304491.0 in Q2 2026, from $310184.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $348757.0 in Q1 2025 and troughed at $66600.0 in Q2 2022.
- A 5-year average of $232497.7 and a median of $306293.5 in 2024 frame the typical range for Treasury Shares.
- The widest annual swing landed in 2022, when Treasury Shares slumped 32.59%; it then surged 159.31% in 2023.
- A 5-year view of Treasury Shares shows it stood at $66600.0 in 2022, then surged by 141.59% to $160900.0 in 2023, then soared by 91.48% to $308096.0 in 2024, then increased by 7.62% to $331574.0 in 2025, then retreated by 8.17% to $304491.0 in 2026.
- Per Business Quant data, the three most recent Treasury Shares figures were $304491.0 in Q2 2026, $310184.0 in Q1 2026, and $331574.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 304,491.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 304,491.00 |
| Jun 30, 2026 | 304,491.00 |
| Mar 31, 2026 | 43,536.00 |
| Mar 31, 2026 | 43,536.00 |
| Dec 31, 2025 | 56,250.00 |
| Dec 31, 2025 | 56,250.00 |
| Sep 30, 2025 | 56,250.00 |
| Sep 30, 2025 | 56,250.00 |
| Jun 30, 2025 | 338,878.00 |
| Jun 30, 2025 | 338,878.00 |
| Mar 31, 2025 | 348,757.00 |
| Mar 31, 2025 | 348,757.00 |
| Dec 31, 2024 | 308,096.00 |
| Dec 31, 2024 | 308,096.00 |
| Sep 30, 2024 | 137,500.00 |
| Sep 30, 2024 | 137,500.00 |
| Jun 30, 2024 | 137,500.00 |
| Jun 30, 2024 | 137,500.00 |
| Mar 31, 2024 | 22,200.00 |
| Mar 31, 2024 | 22,200.00 |